Table des Matières
Publicité
11
Bibliographie
1.
Y. Okada, H. Nagase, and E. D. Harris, Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that di-
gests connective tissue matrix components. Purification and characterization. J.Biol.Chem. 261 (30):14245-14255,
1986.
2.
K. Obata, K. Iwata, Y. Okada, Y. Kohrin, E. Ohuchi, S. Yoshida, M. Shinmei, and T. Hayakawa. A one-step sandwich
enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies.
Clin.Chim.Acta 211 (1-2):59-72, 1992.
3.
J. Martel-Pelletier, R. McCollum, N. Fujimoto, K. Obata, JM. Cloutier, JP. Pelletier. Excess of metalloproteases over
tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.
Lab Invest. 70 (6):807-15, 1994.
4.
S. Sasaki, H. Iwata, N. Ishiguro, K. Obata, and T. Miura. Detection of stromelysin in synovial fluid and serum from pa-
tients with rheumatoid arthritis and osteoarthritis. Clin.Rheumatol. 13 (2):228-233, 1994.
5.
Y. Yoshihara, K. Obata, N. Fujimoto, K. Yamashita, T. Hayakawa, and M. Shimmei. Increased levels of stromelysin-1
and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum. 38 (7):969-
975, 1995.
6.
H. Yamanaka, Y. Matsuda, M. Tanaka, W. Sendo, H. Nakajima, A. Taniguchi, and N. Kamatani. Serum matrix metal-
loproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients
with early rheumatoid arthritis. Arthritis Rheum. 43 (4):852-858, 2000.
7.
M. D. Posthumus, P. C. Limburg, J. Westra, M. A. Van Leeuwen, and M. H. van Rijswijk. Serum matrix metallopro-
teinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with
early rheumatoid arthritis. J.Rheumatol. 29 (5):883-889, 2002.
8.
Katrib, M. D. Smith, M. J. Ahern, J. Slavotinek, L. Stafford, C. Cuello, J. V. Bertouch, H. P. McNeil, and P. P. Youssef.
Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remis-
sion. J.Rheumatol. 30 (1):10-21, 2003.
9.
Tchetverikov, L. R. Lard, J. DeGroot, N. Verzijl, J. M. TeKoppele, F. C. Breedveld, T. W. Huizinga, and R.
Hanemaaijer. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early
rheumatoid arthritis. Ann.Rheum.Dis. 62 (11):1094-1099, 2003.
10. M. J. Green, A. K. Gough, J. Devlin, J. Smith, P. Astin, D. Taylor, and P. Emery. Serum MMP-3 and MMP-1 and pro-
gression of joint damage in early rheumatoid arthritis. Rheumatology.(Oxford) 42 (1):83-88, 2003.
11. Litinsky, D. Paran, D. Levartovsky, I. Wigler, I. Kaufman, I. Yaron, M. Yaron, D. Caspi, O. Elkayam. The effects of
leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheu-
matoid arthritis. Cytokine. 33 (2):106-10, 2006.
12. S. Visvanathan, M. U. Rahman, E. Keystone, M. Genovese, L. Klareskog, E. Hsia, M. Mack, J. Buchanan, M.
Elashoff, and C. Wagner. Association of serum markers with improvement in clinical response measures after treat-
ment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-
FORWARD study. Arthritis Res.Ther. 12 (6):R211, 2010.
13. Mahemara, T. Sugimoto, D. Sugiyama, S. Morinobu, G. Tsuji, S. Kawano, A. Morinobu, and S. Kumagai. Serum Ma-
trix Metalloproteinase-3 as Predictor of Joint Destruction in Rheumatoid Arthritis, Treated with Non-biological Disease
Modifying Anti-Rheumatic Drugs. Kobe J. Med. Sci. 56 (3):98-107, 2010.
14. Y. Urata, R. Uesato, D. Tanaka, Y. Nakamura, and S. Motomura. Treating to target matrix metalloproteinase 3 nor-
malisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis
patients: T-4 Study. Ann.Rheum.Dis., 2011.
15. N. Nishimoto, K. Amano, Y. Hirabayashi, T. Horiuchi, T. Ishii, M. Iwahashi, M. Iwamoto, H. Kohsaka, M. Kondo, T.
Matsubara, T. Mimura, H. Miyahara, S. Ohta, Y. Saeki, K. Saito, H. Sano, K. Takasugi, T. Takeuchi, S. Tohma, T.
Tsuru, Y. Ueki, J. Yamana, J. Hashimoto, T. Matsutani, M. Murakami, and N. Takagi. Drug free REmission/low dis-
ease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod.Rheumatol., 2013.
16. Hiura, S. Iwaki-Egawa, T. Kawashima, S. I. Fujisawa, T. Takeda, H. Komori, and Y. Watanabe. The diagnostic utility
of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic cit-
rullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis. Rheumatol.Int., 2013.
Produkt Ref.:
3168
Produkt Name.
MMP-3
Versionsnummer:.
003 : 2016-09-13
Seite 11 von 11
Publicité
Table des Matières
